These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38503431)

  • 21. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery.
    Despotis GJ; Hogue CW; Saleem R; Bigham M; Skubas N; Apostolidou I; Qayum A; Joist JH
    Anesth Analg; 2001 Jul; 93(1):28-32. PubMed ID: 11429333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery.
    Chomiak PN; Walenga JM; Koza MJ; Reilly TM; Turlapathy P; Pifarre R
    Circulation; 1993 Nov; 88(5 Pt 2):II407-12. PubMed ID: 7993389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of heparin loading during congenital heart operation on thrombin generation and blood loss.
    Turner-Gomes SO; Nitschmann EP; Norman GR; Andrew ME; Williams WG
    Ann Thorac Surg; 1997 Feb; 63(2):482-8. PubMed ID: 9033324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A change in anticoagulation monitoring improves safety, reduces transfusion, and reduces costs in infants on cardiopulmonary bypass.
    Machovec KA; Jooste EH; Walczak RJ; Homi HM; Jaquiss RD; Lodge AJ; Ames WA
    Paediatr Anaesth; 2015 Jun; 25(6):580-6. PubMed ID: 25530420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age-related differences in heparin sensitivity and heparin-protamine interactions in cardiac surgery patients.
    D'Errico C; Shayevitz JR; Martindale SJ
    J Cardiothorac Vasc Anesth; 1996 Jun; 10(4):451-7. PubMed ID: 8776636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with errors in the heparin dose response test: recommendations to improve individualized heparin management in cardiopulmonary bypass.
    Lee MH; Riley W
    Perfusion; 2021 Jul; 36(5):513-523. PubMed ID: 32909506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?
    Dietrich W
    J Cardiovasc Pharmacol; 1996; 27 Suppl 1():S50-7. PubMed ID: 8938284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparin sensitivity test for patients requiring cardiopulmonary bypass.
    DeBois WJ; Liu J; Elmer B; Ebrahimi H; Voevidko L; Lee LY; Krieger KH; Isom WW; Girardi LN
    J Extra Corpor Technol; 2006 Dec; 38(4):307-9. PubMed ID: 17312901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study.
    Riess FC; Poetzsch B; Madlener K; Cramer E; Doll KN; Doll S; Lorke DE; Kormann J; Mueller-Berghaus G
    Thorac Cardiovasc Surg; 2007 Jun; 55(4):233-8. PubMed ID: 17546553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of high-dose heparin on inflammatory and coagulation parameters following cardiopulmonary bypass.
    Paparella D; Al Radi OO; Meng QH; Venner T; Teoh K; Young E
    Blood Coagul Fibrinolysis; 2005 Jul; 16(5):323-8. PubMed ID: 15970715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study.
    Dietrich W; Dilthey G; Spannagl M; Jochum M; Braun SL; Richter JA
    Anesthesiology; 1995 Oct; 83(4):679-89; discussion 29A-30A. PubMed ID: 7574046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates.
    Guzzetta NA; Miller BE; Todd K; Szlam F; Moore RH; Tosone SR
    Anesth Analg; 2005 May; 100(5):1276-1282. PubMed ID: 15845669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?
    Brister SJ; Ofosu FA; Buchanan MR
    Thromb Haemost; 1993 Aug; 70(2):259-62. PubMed ID: 8236131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass.
    Shirota K; Watanabe T; Takagi Y; Ohara Y; Usui A; Yasuura K
    Artif Organs; 2000 Jan; 24(1):49-56. PubMed ID: 10677157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test.
    Wallock M; Jeske WP; Bakhos M; Walenga JM
    Perfusion; 2001 Mar; 16(2):147-53. PubMed ID: 11334198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can the Minimum Protamine Dose to Neutralize Heparin at the Completion of Cardiopulmonary Bypass be Significantly Lower than the Conventional Practice?
    Lee MH; Riley W; Shann KG
    J Extra Corpor Technol; 2021 Sep; 53(3):170-176. PubMed ID: 34658407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heparin-coated cardiopulmonary bypass circuits in coronary bypass surgery.
    Horimoto H; Kondo K; Asada K; Sasaki S
    Artif Organs; 1996 Aug; 20(8):936-40. PubMed ID: 8853810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
    Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
    Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs.
    Henny CP; Ten Cate H; Ten Cate JW; Moulijn AC; Sie TH; Warren P; Büller HR
    J Lab Clin Med; 1985 Aug; 106(2):187-96. PubMed ID: 4020247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.